ArticleBMJ open2025

Matrix-directed therapy losartan to identify the effect on the bone resorption marker carboxy-terminal crosslink of type I collagen telopeptide (CTX) in older adolescents and adults with osteogenesis imperfecta recruited from secondary care sites: the 'MOI-A' study; a randomised, phase 2/pilot, dose-escalating trial.

Mahboobeh Haji Sadeghi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.